Go to the list of all blogs
Allana's Avatar
published in Blogs
Oct 24, 2026
TickeronGET DAILY SIGNALS
Boston Scientific (BSX): Guidance Reset Sets Stage for 2028 Recovery

Boston Scientific (BSX): Guidance Reset Sets Stage for 2028 Recovery

Key Takeaways

  • Guidance reset is the near-term focal point: Management has lowered 2026 expectations to 5%–6% organic revenue growth and adjusted earnings per share (EPS) of $3.28–$3.32, citing a slower U.S. WATCHMAN market and greater-than-expected electrophysiology (EP) share losses.
  • Recovery is being teed up for 2028: Boston Scientific is pointing to seven new launches addressing roughly $25 billion in total addressable market (TAM), including the SEISMIQ 4CE coronary intravascular lithotripsy (IVL) catheter expected in the first half of 2027.
  • Strategic repositioning is underway: The pending Penumbra acquisition and a $1.5 billion investment in MiRus (with an option on its transcatheter aortic valve replacement, or TAVR, system) signal a push into neurovascular and structural-heart growth markets.
  • Cost discipline is a structural lever: A restructuring program targets about $500 million in annual run-rate savings by the end of 2029, with more than half expected by 2027, aimed at protecting margins and funding innovation.
  • Analyst sentiment is constructive but recalibrating: Consensus remains a "Buy," yet several firms have trimmed price targets or shifted to more cautious ratings, reflecting reduced near-term growth visibility.
  • For more detail on Major News, Today's Price Move, Price Targets, and Earnings, explore the dedicated pages for deeper analysis of Boston Scientific.
  • Discover automated strategies and AI-driven approaches by exploring Trending AI Robots.

Strategic Positioning and Competitive Outlook

Boston Scientific operates as a diversified medical-technology company across cardiovascular, endoscopy, urology, neuromodulation, and interventional oncology markets. Its core strengths include a broad, globally distributed portfolio, leadership in pulsed-field ablation (PFA) for atrial fibrillation, and a dominant position in left atrial appendage closure (LAAC) through WATCHMAN. Roughly 75% of revenue comes from business units still growing in the mid-single digits, providing a durable base even as high-growth franchises reset.

The medium-term challenge centers on competitive erosion in two historically fast-growing areas: U.S. electrophysiology, where rivals have gained share, and WATCHMAN, where evolving clinical evidence has softened referral patterns. Management has responded by reorganizing segments, accelerating a pipeline of next-generation catheters and defibrillator platforms, and pursuing scale through acquisitions such as Penumbra. These moves aim to shift the narrative from near-term execution back toward durable, above-market growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Major Catalysts Ahead

The most immediate catalyst is the third-quarter earnings report, expected around October 28, 2026. Guidance calls for organic growth of only 3%–5% and adjusted EPS of $0.80–$0.82, below earlier consensus — making confirmation of the reset and any signs of stabilization in EP and WATCHMAN the key items investors will watch.

Longer-term catalysts include the anticipated close of the Penumbra acquisition in the second half of 2026, the SEISMIQ 4CE launch in the first half of 2027, and the FARAWAVE Ultra mapping and ablation catheter, plus the PRECEDENT defibrillator platform, expected later in 2027. Regulatory clearances such as the recently granted RIVOS and TruSelect approvals also broaden the addressable portfolio. Collectively, these events could reframe investor expectations about when revenue growth returns to or above its weighted average market growth rate.

On analyst ratings, the consensus profile remains a "Buy," with an average price target around $59 based on roughly 31 analysts polled by S&P Global. However, sentiment has become more cautious: Citi downgraded the stock to Neutral, Barclays initiated at Equal Weight, and Argus Research moved to Hold, while multiple firms lowered price targets. This reflects a mix of maintained long-term optimism and reduced near-term confidence.

Industry and Macroeconomic Forces

Medical-device demand is tied to hospital procedure volumes, which are influenced by labor availability, reimbursement policy, and elective-procedure trends. Aging demographics and rising cardiovascular disease prevalence provide a structural tailwind, while competition for hospital capital budgets and value-based procurement — particularly in China, where volume-based purchasing has pressured the urology stone business — act as headwinds.

Interest rates and inflation shape both the cost of capital for Boston Scientific's acquisition strategy and hospital purchasing decisions. With roughly 2.0x gross debt leverage and a strong free-cash-flow profile, the company retains flexibility for deals and buybacks. Geopolitical and trade dynamics also matter given its Asia-Pacific exposure, where double-digit growth in Japan, China, and Korea has been a bright spot.

2026 Outlook and Long-Term Themes to Watch

For 2026, the story is about stabilization. Management expects the second half to remain pressured, with EP roughly flat and WATCHMAN declining mid- to high-single digits, before growth improves meaningfully in 2028. The key is whether the cost-restructuring program and disciplined capital allocation protect profitability during the transition.

Looking further out, several long-term themes will shape the trajectory: expansion into high-growth markets such as intracardiac echocardiography, renal denervation, and structural heart via the MiRus TAVR option; the integration of Penumbra's neurovascular and thrombectomy portfolio; and a return to double-digit adjusted EPS growth as new launches and cost savings converge. Competitive threats from larger rivals in EP and CRM (cardiac rhythm management) remain the principal risk, alongside the possibility that clinical evidence continues to pressure WATCHMAN adoption. Margin sustainability will hinge on product mix and the pace of restructuring benefits.

Consensus expectations remain broadly favorable over a 12-month horizon, but the spread of price targets — and the recent wave of downward revisions — underscores a genuine debate about how quickly growth can reaccelerate. The article does not offer its own price forecast; any price targets referenced reflect external analyst expectations only.

Exploring Tickeron AI Tools for Research

In my analysis of names like BSX, I often turn to Tickeron’s AI Trend Prediction Engine to gauge potential momentum shifts. It provides searchable predictions, historical context, and alerts that help evaluate whether a stock may trend bullish, bearish, or sideways over the coming weeks or months. This tool has become a useful part of my routine for identifying developing trends without replacing core fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BSX

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


BSX in downward trend: price may drop because broke its higher Bollinger Band on October 19, 2026

BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In 20 of the 33 cases the stock fell afterwards. This puts the odds of success at 61%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 50 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.

The Moving Average Convergence Divergence Histogram (MACD) for BSX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 26 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.

BSX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BSX crossed bearishly below the 50-day moving average on November 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 201 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. BSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.485) is normal, around the industry mean (4.142). P/E Ratio (17.169) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of medical devices

Industry MedicalNursingServices

Industry
Medical Specialties
Address
300 Boston Scientific Way
Phone
+1 508 683-4000
Employees
59000
Web
https://www.bostonscientific.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.